Egg prices are still rattling food manufacturers, and The Every Company just made its timing look very smart. The California startup reports a 550% spike in orders for its precision-fermented egg protein. It has now expanded its manufacturing partnership with Huvepharma to quadruple output.
TLDR
- Orders for animal-free egg protein surged 550%, driving urgent capacity expansion.
- Huvepharma partnership now scales production fourfold to meet demand.
- Products already sell at Walmart, Target, and Amazon.
- Precision fermentation offers supply-chain insulation from avian flu disruptions.
- Ingredient-level adoption signals growing B2B appetite for animal-free proteins.
The Every Company’s recombinant egg white protein is already on shelves at Walmart, Target, and Amazon. That retail footprint, combined with ongoing avian flu pressure on conventional egg supply, appears to be accelerating B2B interest fast.
Reporting by Green Queen notes the Californian startup cited a 550% order increase as the trigger for expanding its deal with Bulgarian pharma manufacturer Huvepharma. The new arrangement targets a fourfold increase in production capacity.
Precision-Fermented Egg Protein Finds Its Commercial Moment
Precision fermentation produces proteins identical to animal-derived counterparts, without the animal. For food manufacturers, that means functional parity with conventional egg white, plus insulation from volatile commodity markets.
Avian flu has culled hundreds of millions of laying hens globally since 2022. Conventional egg prices remain elevated and unpredictable. Ingredient buyers are paying attention.
Huvepharma brings established fermentation infrastructure and regulatory experience across pharmaceutical and food-grade manufacturing. The partnership gives The Every Company a credible scale pathway without building its own facilities.
What This Signals for Ingredient Suppliers and Formulators
Additionally, the speed of this expansion reflects a broader shift. Formulators sourcing alternative proteins increasingly want drop-in functionality, not reformulation headaches. Egg white protein, with its binding, foaming, and gelling properties, is notoriously hard to replace.
The Every Company’s precision-fermented egg protein claims functional equivalence. If that holds at scale, it removes a significant barrier for manufacturers weighing the switch.
In short, a 550% demand surge is not a pilot signal. It is a commercialization signal. Suppliers and co-manufacturers watching the alternative protein space should note that this deal structure, startup innovation paired with established pharma fermentation capacity, may become a repeatable model.
Source: Green Queen. https://www.greenqueen.com.hk/the-every-company-egg-white-protein-huvepharma-precision-fermentation/